AVXL Anavex Life Sciences Corp

Price (delayed)

$5.85

Market cap

$495.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$355.77M

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, ...

Highlights
AVXL's quick ratio is up by 33% YoY and by 27% QoQ
The company's EPS rose by 25% YoY and by 7% QoQ
Anavex Life Sciences's equity has decreased by 7% YoY

Key stats

What are the main financial stats of AVXL
Market
Shares outstanding
84.64M
Market cap
$495.15M
Enterprise value
$355.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$40.43M
EBITDA
-$40.43M
Free cash flow
-$32.48M
Per share
EPS
-$0.51
Free cash flow per share
-$0.39
Book value per share
$1.64
Revenue per share
$0
TBVPS
$1.75
Balance sheet
Total assets
$144.52M
Total liabilities
$9.56M
Debt
$0
Equity
$134.96M
Working capital
$134.96M
Liquidity
Debt to equity
0
Current ratio
15.12
Quick ratio
14.58
Net debt/EBITDA
3.45
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-26.8%
Return on equity
-29%
Return on invested capital
N/A
Return on capital employed
-30%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVXL stock price

How has the Anavex Life Sciences stock price performed over time
Intraday
8.53%
1 week
29.71%
1 month
55.17%
1 year
-30.52%
YTD
-37.16%
QTD
38.63%

Financial performance

How have Anavex Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.99M
Net income
-$40.59M
Gross margin
N/A
Net margin
N/A
Anavex Life Sciences's net income has increased by 23% YoY and by 6% QoQ
AVXL's operating income is up by 13% year-on-year and by 3.2% since the previous quarter

Growth

What is Anavex Life Sciences's growth rate over time

Valuation

What is Anavex Life Sciences stock price valuation
P/E
N/A
P/B
3.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 25% YoY and by 7% QoQ
The stock's price to book (P/B) is 54% less than its 5-year quarterly average of 7.2 and 24% less than its last 4 quarters average of 4.3
Anavex Life Sciences's equity has decreased by 7% YoY

Efficiency

How efficient is Anavex Life Sciences business performance
The ROE has grown by 21% YoY and by 4.3% from the previous quarter
AVXL's return on assets is up by 21% year-on-year and by 3.9% since the previous quarter

Dividends

What is AVXL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVXL.

Financial health

How did Anavex Life Sciences financials performed over time
The company's current ratio rose by 33% YoY and by 28% QoQ
AVXL's quick ratio is up by 33% YoY and by 27% QoQ
The debt is 100% smaller than the equity
Anavex Life Sciences's equity has decreased by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.